# US 2014/0348920 A1 · Method of Treating Multiple Sclerosis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0348920 A1
- Document ID: US20140348920A1
- Status: Published application
- Kind: A1
- Application number: 14/458,625
- Filed: 2014-08-13
- Published: 2014-11-27
- Earliest claimed: 2012-07-26
- Assignees: Assistance Publique-Hopitaux de Paris
- Applicants: Assistance Publique Hopitaux De Paris
- Inventors: Frédéric Sedel
- Web page: https://patentgrep.com/patent/US20140348920A1

## CPC

- A61K 31/4188: condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 31/395: having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention provides methods for treating multiple sclerosis by administering biotin. The invention also provides methods for treating sequelae after multiple sclerosis attacks by administering biotin.

## Claims

### Claim 1

A method of treating multiple sclerosis, comprising administering biotin to a patient in need thereof.

### Claim 2 (depends on 1)

The method of claim 1, in which the multiple sclerosis is a progressive form of multiple sclerosis.

### Claim 3

A method for treating sequelae after multiple sclerosis attacks in a patient, comprising administering biotin to said patient.

### Claim 4 (depends on 1)

The method of claim 1, wherein the daily amount of biotin administered to said patient is comprised between 50 and 500 mg.

### Claim 5 (depends on 1)

The method of claim 1, wherein the amount of biotin administered to said patient is comprised between 100 and 300 mg.

### Claim 6 (depends on 1)

The method of claim 1, wherein said biotin is in a form suitable for oral administration.

### Claim 7 (depends on 1)

The method of claim 1, wherein said biotin is in the form of gel capsules, tablets (optionally film-coated), lozenges or pills.

### Claim 8 (depends on 1)

The method of claim 1, wherein said biotin is in the form of a composition containing biotin and excipients, without any other active ingredient.

### Claim 9 (depends on 8)

The method of claim 8, wherein said excipients are chosen from talc and microcrystalline cellulose.

### Claim 10 (depends on 1)

The method of claim 1, wherein said biotin is in the form of an injectable composition.

### Claim 11 (depends on 3)

The method of claim 3, wherein the daily amount of biotin administered to said patient is comprised between 50 and 500 mg.

### Claim 12 (depends on 3)

The method of claim 3, wherein the amount of biotin administered to said patient is comprised between 100 and 300 mg.

### Claim 13 (depends on 3)

The method of claim 3, wherein said biotin is in a form suitable for oral administration.

### Claim 14 (depends on 3)

The method of claim 3, wherein said biotin is in the form of gel capsules, tablets (optionally film-coated), lozenges or pills.

### Claim 15 (depends on 3)

The method of claim 3, wherein said biotin is in the form of a composition containing biotin and excipients, without any other active ingredient.

### Claim 16 (depends on 15)

The method of claim 15, wherein said excipients are chosen from talc and microcrystalline cellulose.

### Claim 17 (depends on 3)

The method of claim 3, wherein said biotin is in the form of an injectable composition.
